Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a research report report published on Tuesday morning.

Several other brokerages also recently weighed in on ATNM. Maxim Group cut their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating on the stock in a research report on Tuesday, August 6th. HC Wainwright decreased their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating on the stock in a research note on Tuesday, August 6th. Finally, B. Riley downgraded shares of Actinium Pharmaceuticals from a buy rating to a neutral rating and cut their price target for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $11.40.

Actinium Pharmaceuticals Trading Up 3.2 %

Shares of Actinium Pharmaceuticals stock opened at $1.63 on Tuesday. Actinium Pharmaceuticals has a one year low of $1.33 and a one year high of $10.24. The business has a fifty day moving average of $2.01. The company has a market cap of $48.55 million, a PE ratio of -0.95 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. As a group, equities research analysts anticipate that Actinium Pharmaceuticals will post -1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals in the first quarter valued at approximately $78,000. The Manufacturers Life Insurance Company acquired a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at $92,000. Renaissance Technologies LLC bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter worth about $142,000. Rhumbline Advisers grew its holdings in shares of Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Actinium Pharmaceuticals during the 2nd quarter worth about $356,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).